Histamine-2 Receptor Antagonist in the Treatment of Gastroesophageal Reflux Disease

[1]  R. Berni Canani,et al.  Gastric acidity inhibitors and the risk of intestinal infections , 2010, Current opinion in gastroenterology.

[2]  Yvan Vandenplas,et al.  Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). , 2009, Journal of pediatric gastroenterology and nutrition.

[3]  Y. Vandenplas,et al.  A biodegradable esophageal stent in the treatment of a corrosive esophageal stenosis in a child. , 2009, Journal of pediatric gastroenterology and nutrition.

[4]  N. Afzal,et al.  Current Pharmacological Management of Gastro-Esophageal Reflux in Children , 2009, Paediatric drugs.

[5]  A. Lopez,et al.  Ranitidine and late-onset sepsis in the neonatal intensive care unit , 2007, Journal of perinatal medicine.

[6]  F. Manguso,et al.  Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children , 2006, Pediatrics.

[7]  John V Guiliana,et al.  Cimetidine as a first-line therapy for pedal verruca: eight-year retrospective analysis. , 2005, Journal of the American Podiatric Medical Association.

[8]  P. Schmittenbecher.  Ranitidine-enhanced 99mtechnetium pertechnetate imaging in children improves the sensitivity of identifying heterotopic gastric mucosa in Meckel's diverticulum: Rerksuppaphol S, Hutson JM, Oliver MR. Pediatr Surg Int 2004 (May);20:323-325 , 2005 .

[9]  S. Orenstein,et al.  Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. , 2005, Clinical therapeutics.

[10]  M. Clementi,et al.  Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. , 2005, Reproductive toxicology.

[11]  K. Bergh,et al.  Gastric juice: a barrier against infectious diseases. , 2005, Basic & clinical pharmacology & toxicology.

[12]  J. Hutson,et al.  Ranitidine-enhanced 99m technetium pertechnetate imaging in children improves the sensitivity of identifying heterotopic gastric mucosa in Meckel’s diverticulum , 2004, Pediatric Surgery International.

[13]  G. Kearns,et al.  Developmental Pharmacokinetics and Pharmacodynamics of Nizatidine , 2004, Journal of pediatric gastroenterology and nutrition.

[14]  G. Kearns,et al.  Famotidine Disposition in Children and Adolescents with Chronic Renal Insufficiency , 2003, Journal of clinical pharmacology.

[15]  G. Kearns,et al.  Single‐Dose Pharmacokinetics of Nizatidine (Axid®) in Children , 2002, Journal of clinical pharmacology.

[16]  M. Robinson,et al.  Determination of the time of onset of action of ranitidine and famotidine on intra‐gastric acidity , 2002, Alimentary pharmacology & therapeutics.

[17]  A. Ciociola,et al.  Ranitidine, 75 mg, over‐the‐counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro‐oesophageal reflux , 2002, Alimentary pharmacology & therapeutics.

[18]  M. Vieth,et al.  The AMOR study: a randomized, double-blinded trial of omeprazole versus ranitidine together with amoxycillin and metronidazole for eradication of Helicobacter pylori , 2001, European journal of gastroenterology & hepatology.

[19]  A. Harrison,et al.  Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children , 2001, Critical care medicine.

[20]  R. Baker,et al.  Guidelines for Evaluation and Treatment of Gastroesophageal Reflux in Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition , 2001, Journal of pediatric gastroenterology and nutrition.

[21]  H. Farrar,et al.  The Pharmacokinetics of Oral Ranitidine in Children and Adolescents with Cystic Fibrosis , 1999, Journal of clinical pharmacology.

[22]  G. Kearns,et al.  Pharmacokinetics and Pharmacodynamics of Famotidine in Children , 1996, Journal of clinical pharmacology.

[23]  N. Narin,et al.  Ranitidine administration in Henoch‐Schönlein vasculitis , 1995, Acta paediatrica Japonica : Overseas edition.

[24]  Cloud Ml,et al.  Nizatidine versus placebo in gastro-oesophageal reflux disease: a 6-week, multicentre, randomised, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group. , 1994 .

[25]  D. Kelly.  Do H2 receptor antagonists have a therapeutic role in childhood? , 1994, Journal of pediatric gastroenterology and nutrition.

[26]  N. Principi,et al.  Ranitidine pharmacokinetics in newborn infants. , 1993, Archives of disease in childhood.

[27]  R. Grand,et al.  Efficacy of cimetidine for gastric acid suppression in pediatric patients. , 1992, The Journal of pediatrics.

[28]  T. Humphries,et al.  Famotidine Relieves Symptoms of Gastroesophageal Reflux Disease and Heals Erosions and Ulcerations: Results of a Multicenter, Placebo-Controlled, Dose-Ranging Study , 1991 .

[29]  T. Humphries,et al.  Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. , 1991, Archives of internal medicine.

[30]  S. Raithel,et al.  [Famotidine dosage in children. The effect of different doses on the pH and volume of the gastric juice]. , 1990, Der Anaesthesist.

[31]  J. Michnovicz,et al.  The effects of cimetidine on the oxidative metabolism of estradiol. , 1989, The New England journal of medicine.

[32]  J. Blumer,et al.  Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. , 1985, The Journal of pediatrics.

[33]  A. Hauser,et al.  Pharmacokinetics and pharmacodynamics of cimetidine and metabolites in critically ill children. , 1985, The Journal of pediatrics.

[34]  A. Somogyi,et al.  Cimetidine pharmacokinetics and dosage requirements in children , 1985, European Journal of Pediatrics.

[35]  S. Bernasconi,et al.  Bradycardia and neurologic disorders associated with ranitidine in a child. , 1985, American journal of diseases of children.

[36]  W. Kirch,et al.  Interactions and Non-interactions with Ranitidine , 1984, Clinical pharmacokinetics.

[37]  K. Isselbacher,et al.  Ranitidine: a new H2-receptor antagonist. , 1983, The New England journal of medicine.

[38]  J. Goodwin.  Mechanism of action of nonsteroidal anti-inflammatory agents. , 1983, Postgraduate medicine.

[39]  C. Coté,et al.  The Dose-Response Effects of Oral Cimetidine on Gastric pH and Volume in Children , 1981 .

[40]  N. Peden,et al.  PHARMACOLOGICALLY EFFECTIVE PLASMA CONCENTRATIONS OF RANITIDINE , 1979, The Lancet.

[41]  K. Isselbacher,et al.  Drug therapy: Cimetidine. , 1978, The New England journal of medicine.

[42]  R. Sturdevant,et al.  Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer. , 1975, The New England journal of medicine.

[43]  G. Giguere,et al.  Ranitidine (Zantac®) Syrup versus Ranitidine Effervescent Tablets (Zantac® EFFERdose®) in Children , 2006, Paediatric drugs.

[44]  G. Kearns,et al.  Pharmacokinetics of Famotidine in Infants , 2005, Clinical pharmacokinetics.

[45]  U. Klotz,et al.  Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery. , 1990, Clinical pharmacokinetics.

[46]  T. Hegyi,et al.  Pharmacokinetic evaluation of cimetidine in newborn infants. , 1985, Clinical therapeutics.